ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN
First Claim
Patent Images
1. A compound of formulae I(A-E) having the following structure:
16 Assignments
0 Petitions
Accused Products
Abstract
The aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepine derivative compounds of the present invention are represented by formulae (I) (A-E) having the following structure where the carbon atom designated * is in the R or S configuration and the substituents X and R1-R9 are as defined herein.
-
Citations
28 Claims
-
1. A compound of formulae I(A-E) having the following structure:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
2. The compound according to claim 1, wherein X is substituted phenyl and R4 is substituted monocyclic or bicyclic aryl or heteroaryl.
-
3. The compound according to claim 1, wherein X is substituted bicyclic aryl or heteroaryl and R4 is substituted monocyclic or bicyclic aryl or heteroaryl.
-
4. The compound according to claim 1, wherein X is substituted phenyl and R4 is H, —
- OR12, —
S(O)nR13, C(O)R13, —
NR10R11, —
CN, halogen, and C1-C6 alkyl, wherein each of the C1-C6 alkyl is optionally substituted from 1 to 3 times with substituents as defined in R15.
- OR12, —
-
5. The compound according to claim 1, wherein X is substituted bicyclic aryl or heteroaryl and R4 is H, —
- OR12, —
S(O)nR13, —
C(O)R13, —
NR10R11, —
CN, —
S(O)nR13, halogen, and C1-C6 alkyl, wherein each of the C1-C6 alkyl is optionally substituted from 1 to 3 times with substituents as defined in R15.
- OR12, —
-
6. The compound according to claim 1, wherein X is substituted monocyclic heteroaryl and R4 is substituted monocyclic or bicyclic aryl or heteroaryl.
-
7. The compound according to claim 1, wherein:
-
X is phenyl, optionally substituted from 1 to 4 times with substituents as defined in R14; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or gem-dimethyl; R3 is H, methyl, hydroxyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, difluoromethoxy or trifluoromethoxy; R5 is H, fluoro, chloro, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, hydroxyl or methoxy; R6 is H, fluoro, chloro, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, hydroxyl or methoxy; R7 is H, gem-dimethyl, or C1-C4 alkyl, where each of the C1-C4 alkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; R8 is H, hydroxyl, fluoro, chloro, methyl, C1-C3 alkyl optionally substituted with hydroxyl or amino, or amino optionally substituted with C1-C3 alkyl; and R9 is H, fluoro, chloro, methyl, hydroxyl, or cyano.
-
-
8. The compound according to claim 7, wherein:
R4 is H, halogen, —
OR12, —
S(O)nR13, —
CN, —
C(O)R13, —
NR10R11, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, or C4-C7 cycloalkylalkyl, wherein each of the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 3 times with substituents as defined in R15.
-
9. The compound according to claim 7, wherein R4 is phenyl, pyridyl, 2-oxo-pyridin-1(2H)-yl, pyrimidinyl, pyridazinyl, 6-oxopyridazin-1(6H)-yl, pyrazinyl, triazinyl, pyranyl, furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indanyl, indenyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indolinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, indazolyl, benzimidazolyl, benzooxazolyl, benzothiazolyl, benzoisoxazolyl, benzoisothiazolyl, benzotriazolyl, benzo[1,3]dioxolyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, pthalazinyl, quinoxalinyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 4H-chromenyl, indolizinyl, quinolizinyl, 6aH-thieno[2,3-d]imidazolyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, thieno[2,3-b]furanyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, furo[2,3-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-d]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[2,3-b]pyrazinyl, imidazo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, 2-oxo-2,3-dihydrobenzo[d]oxazolyl, 3,3-dimethyl-2-oxoindolinyl, 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, benzo[c][1,2,5]oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, [1,2,4]triazolo[4,3-a]pyrazinyl, 3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl, oxooxazolidin-3-yl, optionally substituted from 1 to 4 times with substituents as defined in R14.
-
10. The compound according to claim 1, wherein:
-
X represents a 5- or 6-membered monocyclic heterocycle selected from the group consisting of pyridyl, 2-oxo-pyridin-1(2H)-yl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyranyl, pyrrolyl, furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, and tetrazolyl, optionally substituted from 1 to 4 times with substituents as defined in R14; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or gem-dimethyl; R3 is H, methyl, hydroxyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, difluoromethoxy or trifluoromethoxy; R5 is H, fluoro, chloro, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, hydroxyl or methoxy; R6 is H, fluoro, chloro, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, hydroxyl or methoxy; R7 is H, gem-dimethyl, or C1-C4 alkyl, where each of the C1-C4 alkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; R8 is H, hydroxyl, fluoro, chloro, methyl, C1-C3 alkyl optionally substituted with hydroxyl or amino, or amino optionally substituted with C1-C3 alkyl; and R9 is H, fluoro, chloro, methyl, hydroxyl, or cyano.
-
-
11. The compound according to claim 10, wherein:
R4 is H, halogen, —
OR12, —
S(O)nR13, —
CN, —
C(O)R13, —
NR10R11, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, or C4-C7 cycloalkylalkyl, wherein each of the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 3 times with substituents as defined in R15.
-
12. The compound according to claim 10, wherein R4 is phenyl, pyridyl, 2-oxo-pyridin-1(2H)-yl, pyrimidinyl, pyridazinyl, 6-oxopyridazin-1(6H)-yl, pyrazinyl, triazinyl, pyranyl, furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indanyl, indenyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indolinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, indazolyl, benzimidazolyl, benzooxazolyl, benzothiazolyl, benzoisoxazolyl, benzoisothiazolyl, benzotriazolyl, benzo[1,3]dioxolyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, pthalazinyl, quinoxalinyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 4H-chromenyl, indolizinyl, quinolizinyl, 6aH-thieno[2,3-d]imidazolyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, thieno[2,3-b]furanyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, furo[2,3-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-d]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[2,3-b]pyrazinyl, imidazo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, 2-oxo-2,3-dihydrobenzo[d]oxazolyl, 3,3-dimethyl-2-oxoindolinyl, 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, benzo[c][1,2,5]oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, [1,2,4]triazolo[4,3-a]pyrazinyl, 3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl, oxooxazolidin-3-yl, optionally substituted from 1 to 4 times with substituents as defined in R14.
-
13. The compound according to claim 1, wherein:
-
X is a [5,5]-, [6,5]-, [6,6]-, or [6,7]-fused bicyclic carbocycle or heterocycle selected from the group consisting of indenyl, indanyl, benzofuranyl, benzothiophenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolyl, isoindolyl, indolinyl, benzo[1,3]dioxolyl, benzooxazolyl, benzothiazolyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, benzoimidazolyl, benzotriazolyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4H-chromenyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, indolizinyl, quinolizinyl, 6aH-thieno[2,3-d]imidazolyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]furanyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, furo[2,3-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-c]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[2,3-b]pyrazinyl, benzo[c][1,2,5]oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, imidazo[1,2-a]pyrazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, 2-oxo-2,3-dihydrobenzo[d]oxazolyl, 3,3-dimethyl-2-oxoindolinyl, 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, benzo[c][1,2,5]oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, [1,2,4]triazolo[4,3-a]pyrazinyl, and 3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl, optionally substituted from 1 to 4 times with substituents as defined in R14; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or gem-dimethyl; R3 is H, methyl, hydroxyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, difluoromethoxy or trifluoromethoxy; R5 is H, fluoro, chloro, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, hydroxyl or methoxy; R6 is H, fluoro, chloro, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, hydroxyl or methoxy; R7 is H, gem-dimethyl, or C1-C4 alkyl, where each of the C1-C4 alkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; R8 is H, hydroxyl, fluoro, chloro, methyl, C1-C3 alkyl optionally substituted with hydroxyl or amino, or amino optionally substituted with C1-C3 alkyl; and R9 is H, fluoro, chloro, methyl, hydroxyl, or cyano.
-
-
14. The compound according to claim 13, wherein:
R4 is H, halogen, —
OR12, —
S(O)nR13, —
CN, —
C(O)R13, —
NR10R11, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, or C4-C7 cycloalkylalkyl, wherein each of the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 3 times with substituents as defined in R15.
-
15. The compound according to claim 13, wherein R4 is phenyl, pyridyl, 2-oxo-pyridin-1(2H)-yl, pyrimidinyl, pyridazinyl, 6-oxopyridazin-1(6H)-yl, pyrazinyl, triazinyl, pyranyl, furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indanyl, indenyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indolinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, indazolyl, benzimidazolyl, benzooxazolyl, benzothiazolyl, benzoisoxazolyl, benzoisothiazolyl, benzotriazolyl, benzo[1,3]dioxolyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, pthalazinyl, quinoxalinyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 4H-chromenyl, indolizinyl, quinolizinyl, 6aH-thieno[2,3-d]imidazolyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, thieno[2,3-b]furanyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, furo[2,3-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-d]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[2,3-b]pyrazinyl, imidazo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, 2-oxo-2,3-dihydrobenzo[d]oxazolyl, 3,3-dimethyl-2-oxoindolinyl, 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, benzo[c][1,2,5]oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, [1,2,4]triazolo[4,3-a]pyrazinyl, 3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl and oxooxazolidin-3-yl, optionally substituted from 1 to 4 times with substituents as defined in R14.
-
16. The compound according to claim 1, wherein:
-
X is thiophenyl, thiazolyl, pyridinyl, phenyl, naphthyl, benzo[b]thiophenyl, benzofuranyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, or 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazinyl, optionally substituted with from 1 to 3 substituents selected independently from the group consisting of fluoro, chloro, bromo, methoxy, hydroxyl, cyano, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, substituted C1-C3 alkyl, methanesulfonyl, carbamoyl, C1-C3 alkyl-substituted carbamoyl, and acetamido; R1 is H, methyl, ethyl, isopropyl; R2 is H or gem-dimethyl; R3 is H, chloro or fluoro; R4 is H, methoxy, hydroxyl, methyl, fluoro, bromo, cyano, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, acetyl, aminomethyl, 1-aminocyclopropyl, morpholinomethyl, 2-hydroxypropan-2-yl, morpholine-4-carbonyl, 2-morpholinoethoxy, 2-(dimethylamino)ethyl(methyl)amino, 2-hydroxyethylamino, piperidin-1-yl, piperidin-2-yl, pyrrolidin-1-yl, piperidin-4-ol, morpholino, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-(ethylsulfonyl)piperazin-1-yl, 4-(2-(isopropylamino)-2-oxoethyl)piperazin-1-yl, 4-(pyridin-2-yl)piperazin-1-yl, 4-(pyrimidin-2-yl)piperazin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxopiperidin-1-yl, 6-methylpyridazin-3-yloxy, 6-aminopyridazin-3-yloxy, pyridazin-3-yloxy, pyrazin-2-yloxy, 3-aminopyrazin-2-yloxy, 5-aminopyrazin-2-yloxy, 6-aminopyrazin-2-yloxy, 1,2,4-oxadiazol-3-yl, 3,5-dimethylisoxazol-4-yl, 1H-pyrazol-4-yl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-(methanesulfonyl)phenyl, 3-(methanesulfonyl)phenyl, 2-(methanesulfonyl)phenyl, carbamoylphenyl, pyridinyl, aminopyridinyl, pyridazin-3-yl, 6-methylpyridazin-3-yl, 6-(trifluoromethyl)pyridazin-3-yl, 6-(difluoromethyl)pyridazin-3-yl, 6-((difluoromethoxy)methyl)pyridazin-3-yl, 6-aminopyridazin-3-yl, 6-(methylamino)pyridazin-3-yl, 6-(dimethylamino)pyridazin-3-yl, 6-morpholinopyridazin-3-yl, 6-(4-hydroxypiperidin-1-yl)pyridazin-3-yl, 6-(4-methylpiperazin-1-yl)pyridazin-3-yl, 6-(hydroxymethyl)pyridazin-3-yl, 6-(methoxycarbonyl)pyridazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, 3-aminopyrazin-2-yl, 5-aminopyrazin-2-yl, 6-aminopyrazin-2-yl, 2-oxopyridin-1(2H)-yl, 2-oxopyrrolidin-1-yl, 6-oxo-1,6-dihydropyridazin-3-yl, 6-oxopyridazin-1(6H)-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrazin-3-yl, 3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl, 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, [1,2,4]triazolo[4,3-a]pyridin-6-yl, 3,3-dimethyl-2-oxoindolin-5-yl, 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 3-methyl-[1,2,4]triazolo[4,3-b]-pyridazinyl, [1,2,4]triazolo[4,3-b]-pyridazinyl, or oxooxazolidin-3-yl; R5 is H, chloro or fluoro; R6 is H, chloro or fluoro; R7 is H; R8 is H, fluoro, methyl, or hydroxyl; and R9 is H or hydroxyl.
-
-
17. The compound according to claim 1, wherein the carbon atom designated * is in the R configuration.
-
18. The compound according to claim 1, wherein the carbon atom designated * is in the S configuration.
-
19. The compound according to claim 1, wherein the compound is a (+) stereoisomer.
-
20. The compound according to claim 1, wherein the compound is a (−
- ) stereoisomer.
-
21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound according to claim 1.
-
22. A method of treating a disorder which is created by or is dependent upon decreased availability of norepinephrine, dopamine, or serotonin, said method comprising:
administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
-
23. The method according to claim 22, further comprising:
administering a therapeutically effective amount of a serotonin 1A receptor antagonist or a pharmaceutically acceptable salt thereof.
-
24. The method according to claim 23, wherein the serotonin 1A receptor antagonist is WAY 100135 or spiperone.
-
25. The method according to claim 22, further comprising:
administering a therapeutically effective amount of a selective neurokinin-1 receptor antagonist or a pharmaceutically acceptable salt thereof.
-
26. The method according to claim 22, further comprising:
administering a therapeutically effective amount of a norepinephrine precursor or a pharmaceutically acceptable salt thereof.
-
27. The method according to claim 26, wherein the norepinephrine precursor is L-tyrosine or L-phenylalanine.
-
28. The method according to claim 22, wherein the disorder is selected from the group consisting of:
- lower back pain, attention deficit hyperactivity disorder (ADHD), cognition impairment, anxiety disorders, generalized anxiety disorder (GAD), panic disorder, bipolar disorder or manic depression or manic-depressive disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), major depressive disorder (MDD), postnatal depression, dysthymia, depression associated with Alzheimer'"'"'s disease, Parkinson'"'"'s disease, or psychosis, supranuclear palsy, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, analgesia, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol and amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, Parkinson'"'"'s disease, late luteal phase syndrome or narcolepsy, psychiatric symptoms, anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorders, restless leg syndrome (RLS), tardive dyskinesia, supranuclear palsy, sleep related eating disorder (SRED), night eating syndrome (NES), stress urinary incontinence (SUI), migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome (FS), chronic fatigue syndrome (CFS), sexual dysfunction, premature ejaculation, male impotence, and thermoregulatory disorders.
-
2. The compound according to claim 1, wherein X is substituted phenyl and R4 is substituted monocyclic or bicyclic aryl or heteroaryl.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAlbany Molecular Research Incorporated
-
Original AssigneeAlbany Molecular Research Incorporated, Bristol-Myers Squibb Company
-
InventorsYang, Yuh-lin Allen, Molino, Bruce F., Olson, Richard E., Liu, Shuang, Sambandam, Aruna
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/213.10
-
CPC Class CodesA61P 13/00 Drugs for disorders of the ...A61P 15/00 Drugs for genital or sexual...A61P 15/10 for impotenceA61P 21/00 Drugs for disorders of the ...A61P 25/00 Drugs for disorders of the ...A61P 25/02 for peripheral neuropathiesA61P 25/04 Centrally acting analgesics...A61P 25/06 Antimigraine agentsA61P 25/16 Anti-Parkinson drugsA61P 25/18 Antipsychotics, i.e. neurol...A61P 25/22 AnxiolyticsA61P 25/24 AntidepressantsA61P 25/28 for treating neurodegenerat...A61P 25/30 for treating abuse or depen...A61P 25/32 Alcohol-abuseA61P 25/34 Tobacco-abuseA61P 3/04 Anorexiants; Antiobesity ag...A61P 3/10 for hyperglycaemia, e.g. an...C07D 223/16 Benzazepines; Hydrogenated ...C07D 401/04 directly linked by a ring-m...C07D 401/14 : containing three or more he...C07D 403/04 : directly linked by a ring-m...C07D 471/04 : Ortho-condensed systems